# Healthcare Podcast Weekly Digest: April 18–24, 2026 > Healthcare investor newsletter for April 18–24, 2026. UnitedHealth's blowout Q1 turnaround squares off against valuation skeptics, while Eli Lilly's oral GLP-1 launch, the Kelonia CAR-T deal, and an Amazon/Hims pharmacy reconfiguration redraw the obesity battle map. ## The Healthcare Investor Brief ### Week of April 18–24, 2026 --- ```request-access variant: ghost heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## This Week's Big Picture Healthcare had a defining week. UnitedHealth (UNH) reported a blowout Q1: adjusted EPS $7.23 vs. $6.61 consensus, MCR of 83.9% (down 90 bps y/y), and a guidance raise to ">$18.25," driving shares ~8% higher and triggering a wave of sell-side price-target hikes ($287 at Baird to $420 at Piper Sandler). In parallel, the GLP-1 obesity battle entered a new phase: Eli Lilly (LLY) launched the first oral pill, Foundayo (orforglipron), at $149/month cash pay, struck a $7B deal for in-vivo CAR-T player Kelonia Therapeutics, and opened LillyDirect distribution to Hims & Hers. The week's clear debate: is managed care's turnaround durable, or is UNH already priced for perfection as the DOJ upcoding and antitrust investigations stay open? --- ## 👥 Key People This Week | Speaker | Affiliation | Topic | Key Quote / Takeaway | | --- | --- | --- | --- | | Stephen Hemsley | CEO, UnitedHealth Group | UNH Q1 turnaround | "We are continuing to help simplify and modernize health care... bringing greater value, affordability, transparency and connectivity" | | Bobby Hunter | Chief of Government Programs, UNH | BALANCE Model for GLP-1s | "We'd like to find a path to yes there on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure" | | Jim Cramer | CNBC, Squawk on the Street | UNH re-rate | "UnitedHealth, David, it's the old UnitedHealth. They're back... UNH guides up and it sets the tone" ([Squawk on the Street](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOglavA94VgO9SzqIWCK7LtYgRbge6YFefmuB2tH6CL5jLXNFg2BzCKw1ewhxqDoxRmfRHy62HhWhLkrWfegXomxknD7-2BMb-2FFlOvfUKuinw9JQ-3D-3DMwSI_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54qu1RCdFPiNFPaMy44-2BWf4nV4vt9JsFZF46XWTlkn8tkNeJPxGdj-2BGeH1iuU5W2aJGQupq-2BHKSstxyjETlsFTJ9rRExB9fKABC16rtpWTyHPLWWzGr53jkXq8odv5AHJ1g-3D-3D)) | | Ann Berry | Brew Markets | UNH / Amazon GLP-1 | UNH "surging over 8% today... raised its 2026 profit outlook"; Amazon One Medical "unveiling... weight management program with upfront GLP-1 medication costs covered" ([Brew Markets](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjtav12niUMNSn49mvn6b8P4PjgAqlRPPCuZCt5jvRWgr56kGnu0FFC-2Fwo9868KxN-2BFPNLhFcQqnWgydyuxqs6LLIzUYKPXK1k3Cujh-2B36FWw-3D-3DHYSO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54usOlATcCd-2FFjTnK9YS566QgwXuLJeMvWl1cYMyp95v2t-2FFRNOUsGXpSFSO5XulPAP8V97gY3eM38UIyIsny04LWtacR7YpftHUZ0gSLvOwKuEvVEuYo-2BEITfLVrkzqXVw-3D-3D)) | | Alex Karnal | Braidwell (healthcare specialist) | GLP-1 market & PCSK9 | "This is a class of medicines will easily be in excess of $100 billion a year in revenue"; GLP-1 new scripts went "from 200,000 a week to 300,000 a week in just a few months' time" ([Invest Like the Best](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgwlKuGttsd3Mz0lWvxs8UIQOezZXf9Yu9ofDQTpgHKEMTbYihaAi18Hm673Ijpsvr4csm826tmGR-2F0tmb3lpN-2BRm5bJNqLnN1i-2BV3UTKh2vQ-3D-3DFAAy_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54ubCXp3KLaJ-2B6F6jgZAq7nHMHmi8vYG3Z7LYBHI7X3qWSkgKUQLnD2R1IVyh-2B-2B7BXizhw-2Bayyla-2B7cy48vS0USkxtaANH-2Fgw3nGHYr1MiN3e94tVb8npxGkhJdfJGaFnfQ-3D-3D)) | | Dave Knapp | Host, On The Pen GLP-1 News | Lilly dual-lane strategy | Lilly executing "an absolute masterclass... extracts maximum value out of a pharmaceutical drug or multiple... that could potentially even compete with each other amidst political and regulatory chaos" ([On The Pen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgKJjbpH-2FkkM4a-2B-2F0Rwt6wyImQtFtfN7gqsf5-2FKj8wjc9QgngaY7zqp8WzkdFBTu0VvpdITttWJx9QMlnWKMqg1MmIAZeb-2F39aVysL28dT9Sw-3D-3DQjPh_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54pcX-2BacvLWswjNjfkafSUnO62bKYh1dy6Lw8Y4RxSe8llZTgwYMJo5pTvZoKQXCBnmc2VIUHp8FIX2fd9E2R4N0OiKFSyNTsg0mAgx4BQN-2FUXHWlN48IvhBE4S1B-2BEsfAw-3D-3D)) | | Jason Wallace | Telltales | UNH nuance / Kelonia / FDA peptides | "The elevated utilization of health care resources remained elevated"; on Kelonia's in-vivo CAR-T: "use a virus to... modify them to be cancer-fighting... all occurs right in your body" ([Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOirhzPegG85cXoUgPxDb7aS3WZmpbbC5hMqtvECzgiMwbog3msksi6vAfy-2Fot8Cl6jZCrC6LEdv4BuhWprZs-2FYbCWj6L4YUwnm6pCqhOPCKkA-3D-3DvcrY_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54jALJ13DkyxkkSjs7yXzyAKP7VaMuxnGtrZJ8BetV2W9Txy2e77mQdQFaH5dvd-2B7sCkspNf7ELrbsm-2B0Vnln6wYQLKfm39AkdzTmkVvGL6-2FiiJxwgrEqZgVeyfzbTDL5OQ-3D-3D)) | | Ava Cabot / Marcus Graham | Telltales Weekend Update | UNH pre-earnings setup | UNH at "3.7x trailing free cash flow" with "26% free cash flow yield"; "If UNH beats, managed care re-rates" ([Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjKXhPgQj-2FqoQzjop2G3kAOXt5F0OoJ0rujDHfVQMgizsOjpYOzPCnCoXK9kJPpr1-2FCSFag4tV-2FuRtVpVhAaBNc4ScV8dmCuGxXdGy5zvtWYA-3D-3DL-1K_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54tbiBJIOt7fBd-2BbmyZk-2FZoAvQWatsC-2FYdDQlHynbtzgsyZAVCeiLARwXCFYLJMaIumhuodGBfLGLXA4tBnmE2TbtSyIK-2FR3rbg7-2BVpEM9-2BII-2Fcsj3U8nwr9PnCJP5z-2B4UQ-3D-3D)) | | Deep Values hosts | Deep Values podcast | UNH valuation | "The chasm between the market asking price of $314 and the intrinsic business value of $204 represents a complete lack of a margin of safety" ([Deep Values](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgV3h26SZXwcsYB9EiNOQUb-2BjJvhZK7vb-2Bat4LVxXSdN-2FdfJw9DtZObV5PvtOdTMEFj5o3BX5yOsQ8stRNnAlIF-2FTIuht57CHdYfn0S-2Bdfsdw-3D-3DScwD_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54hH94jZulcLXoCj24I9FO7d0u6xqCia1HaZ2U6jX6fNK-2BwSFjFVonJnBIPoAhzMDvEyBji3Nyp1rbgP8roPUrsMaUjtEy-2FDwWeuCOs4bcGvTg9t2ZARnGNbtFuOCUFLcXA-3D-3D)) | | Rachel Warren / Lou Whiteman | Motley Fool Money | Amazon GLP-1 disruption | Amazon GLP-1 "could be more disruptive to your traditional pharmacy chains like CVS, per se, than necessarily the telehealth companies" ([Motley Fool Money](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOirhzPegG85cXoUgPxDb7aSxN5WWw9N8L8YBrq8fd4yXoV0u7jHwRQ3HZhVJ5rsH88ed2mTowXH-2BwGEo7hOI1b7YgaEnhW14On-2FUuU7sFOjWg-3D-3Dgh1H_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54kRUiyiO51YWhRcfGcMbs6p8IR4u8y12k2sRQJZE3jrfjY41kBBLyOfPQedK6ITruf7DYciForcbAdZUNAVsO-2FQX8kOsbLcxnvrnJNqlM8e5SDAdEReweEtBPsBaIZDtRg-3D-3D)) | | Andrew Dudum | CEO, Hims & Hers | LillyDirect integration | "Providers on our platform can now send prescriptions for Zepbound vials and KwikPen, as well as Foundayo, to the LillyDirect pharmacy and access self-pay pricing" (via X, Apr 23) | | Ryan Dietrich | Chief Market Strategist, Carson Group | Sector rotation | Preference for cyclicals (industrials, financials, tech) over defensives, an implied tilt away from defensive healthcare ([Brew Markets](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjtav12niUMNSn49mvn6b8P4PjgAqlRPPCuZCt5jvRWgr56kGnu0FFC-2Fwo9868KxN-2BFPNLhFcQqnWgydyuxqs6LLIzUYKPXK1k3Cujh-2B36FWw-3D-3DNqvD_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54kraeRKWBhot1wQtoSTlzVhS7spIUoJUHWuIryk4RhyGJqZTa3w2y-2BM1Dn4RtAsUFjX-2Bd0yL6m6csKsEyA2gHMx1q52ObSKDaIuCfph8GnG25woxpzvt-2FeEeXQ5XNCQqRA-3D-3D)) | --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 🔥 Hot Topics **UnitedHealth Group (UNH), the stock of the week.** Q1 revenue $111.7B (vs. $109.66B consensus), adjusted EPS $7.23 (vs. $6.61), MCR 83.9% (down 90 bps y/y), FY26 adjusted EPS guide raised to ">$18.25." Management committed to $1.5B of AI investment in 2026 and an accelerated $2B+ buyback by end of Q2. Stephen Hemsley on the call: "encouraged by the way the year has started" and "comfortable with pricing posture coming into 2026." Optum Health target margins affirmed at 6%–8%. Deep Values detailed the operational mechanics: Optum consolidated from "18 EMR systems to 3" and over "80% of member service calls" are now routed through AI tools, targeting "$1 billion in operating cost reductions" in 2026 ([Deep Values](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgV3h26SZXwcsYB9EiNOQUb-2BjJvhZK7vb-2Bat4LVxXSdN-2FdfJw9DtZObV5PvtOdTMEFj5o3BX5yOsQ8stRNnAlIF-2FTIuht57CHdYfn0S-2Bdfsdw-3D-3D8iPt_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54jtcU04rxAbV8le2TnLp6LIeQgk-2BaKpYkAEuhNziNgAYp70nNtaWtafYWfa5nQmW1IqPq89TN5k5nfJz28URDvq6EzWg5vCtjZ6ImpSW7Oo3CL62D1ox6ms5cc1LNHI5kA-3D-3D)). Post-earnings sell-side reaction was near-universally positive: Evercore ISI to $400, Oppenheimer to $405, Piper Sandler to $420, Wells Fargo to $397, RBC to $400, Argus upgraded to Buy, though Baird (Underperform, $287) and TD Cowen (Hold, $337) stayed cautious on Optum Insight and medium-term margin visibility. **Foundayo (orforglipron), Lilly's oral GLP-1 launch.** Launched in mid-April at a $149/month cash-pay starter dose, matching Novo's oral Wegovy. Jefferies/IQVIA tracking showed 1,390 scripts in launch week, behind oral Wegovy's 3,071 in January but ahead of injectable Zepbound (1,100) and injectable Wegovy (768) at their respective launches. Jefferies projects $1.6B in sales this year and peak annual sales of $30B ([biopharmadive.com](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nj6bujixd4sULtqXs3KXTyNcZNKJQXxArtCH0bXYz3u61aIDm5kdTfqN5u8uOHJB0d7LxCToansg2HB7yuZ-2Bd6JmtqzL0EVjwSwQ0KmaclR5rDrNOkxVJdSlNuf2xqPrKw-3D-3Dd0rg_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54qA2qDmzem2zkggrlWFxGseKrcJsK7a-2B2x1DR3O5J-2F95Gb6W-2FenBEconYq2oRIo-2Boc87CMBJ1vvrLXCW1DVQUPD4Bg8Pq3JKkxNWEf2xJGqyswFYuA9HTOPR1opsDhFAbw-3D-3D), [fiercepharma.com](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NorSeiv-2BtvhOFU8-2F32T8ecM-2BirjJpN-2BL0rhfqSScEfF83kTUj4WrjnarbiwFdymhBX2YW-2Fn4vFiVvuFz5-2FlXZMLGJqorT066LaIcMmPyz7n8nBlNOpv-2BvdwYT8BO0AZzjSv9T8hmRbPgN-2F72-2BWj1keo-3DDl18_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54mouR8QeevaYJ-2BZeERpsX1mAGma3fn85HFG3-2F6tNHhvVir0aUcMUur2p5dQ6BoVNo7l6zmbnG1zDhfm4EA7SXsxSVXo-2BZ2fFU58KuYeAmKSoHzo0Be-2B2-2BRzVQVjW7WFw2w-3D-3D)). Dave Knapp on Lilly's commercial architecture: tirzepatide stays on Lilly Direct at ~$250–$500/month as the high-volume access-friendly drug; retatrutide (2027) targeted as the premium biologic at ~$7,000/month if the biologic classification battle succeeds ([On The Pen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgKJjbpH-2FkkM4a-2B-2F0Rwt6wyImQtFtfN7gqsf5-2FKj8wjc9QgngaY7zqp8WzkdFBTu0VvpdITttWJx9QMlnWKMqg1MmIAZeb-2F39aVysL28dT9Sw-3D-3D38a8_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54jF5UQY9Rb-2BLNp-2BSm-2FwwRJALcPcAPIX9B7fdlcTFfcdj69NH9euCjNMEE0ZTNa7NamrFEanpqI6ItN1vn-2BIKlIlxO-2BJClZsYlbZML-2F0DEOcs3-2BpScb2pari1Jftye6nJgw-3D-3D)). ACHIEVE-4 Phase 3 data for Foundayo: non-inferior MACE vs. insulin glargine, superior A1C/weight benefits, and "risk of all-cause death was 57% lower" vs. insulin glargine. Lilly plans FDA submission for T2D by end of Q2 under the Commissioner's National Priority Review Voucher. **Oral Wegovy acceleration.** Karnal: "the oral version of Wagovi is setting record after record... an almost 4x relative launch cycle for the oral Wagovi versus the most recent injectable launch, Zepbound. People that want these medicines... it costs $150 a month." He framed the adoption driver as pricing elasticity: "at the lower end of the curve, if we get to an $1,800 a year cost, these medicines fly off the shelves" ([Invest Like the Best](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgwlKuGttsd3Mz0lWvxs8UIQOezZXf9Yu9ofDQTpgHKEMTbYihaAi18Hm673Ijpsvr4csm826tmGR-2F0tmb3lpN-2BRm5bJNqLnN1i-2BV3UTKh2vQ-3D-3DWneR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54kY8G9xN3KUh-2FSj99JlV0zQefZOyP1dzN28H3R7uiZ1OIuXQjipKn0utHcmqeRxlMshDC552jX36a-2BTllbxZg8Lqty18XVl7OdeBt-2FDNQ1AqC-2FFJVDjth7sgbxHB81ddLA-3D-3D)). GLP-1 new scripts per week accelerated from ~200k to ~300k in a few months, a ~50% step-up. **CVS/Amazon/Hims pharmacy reconfiguration.** CVS announced it would opt out of the CMS BALANCE Model for GLP-1 Medicare coverage on April 21, sending LLY -3% and NVO -2% intraday. On April 23, Hims & Hers announced LillyDirect prescribing access for Zepbound vials, KwikPen, and Foundayo, with HIMS up ~7% pre-market. Leerink kept Market Perform citing unclear economics. The Motley Fool Money panel argued Amazon's GLP-1 distribution expansion (4,500 cities by year-end) is more of a threat to traditional pharmacy than to telehealth. **AI in healthcare.** Beyond UNH's $1.5B/year commitment, Karnal described a structural shift in drug discovery at companies like Lila Sciences and Enabla: agentic systems can "crack that code" for a molecule in "a month's time" vs. "a couple years" previously. FDA is also deploying AI to screen filings under Commissioner Makary ([Invest Like the Best](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgwlKuGttsd3Mz0lWvxs8UIQOezZXf9Yu9ofDQTpgHKEMTbYihaAi18Hm673Ijpsvr4csm826tmGR-2F0tmb3lpN-2BRm5bJNqLnN1i-2BV3UTKh2vQ-3D-3DNdMm_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54vSOfFhikd6-2B-2FkIuwVmaxAc0Wy4fDd5MpmVBaCAMzgxkuuHlyYAcMEoxOATt-2BCRBzva7FyahSD4VIXgvTZeKuvikgSh5Os5NKX8gP6rtyzpukaH2IvA7-2FmwS3EO11B5yHA-3D-3D)). --- ## ⚔️ Key Debates (Bull vs. Bear) **Debate 1: UnitedHealth, durable turnaround or late-cycle chase?** - **Bull:** Jim Cramer: "They're back... taking up the whole bit, the whole industry." Cabot/Graham argued the pre-earnings 3.7x FCF / 26% FCF yield priced "a permanent impairment" that was refuted by the print. CMS's 2.48% MA rate bump for 2027 is "the first favorable rate rule in three years." Sell-side median PT moved to ~$390–$400 with many $400+ calls (Piper $420, Oppenheimer $405, Argus $400, RBC $400, Evercore $400). - **Bear:** Deep Values: intrinsic value $204 (Buffett Owner Earnings), DCF average $294, "the chasm between the market asking price of $314 and the intrinsic business value of $204 represents a complete lack of a margin of safety"; recommend entry $240–$270 ([Deep Values](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgV3h26SZXwcsYB9EiNOQUb-2BjJvhZK7vb-2Bat4LVxXSdN-2FdfJw9DtZObV5PvtOdTMEFj5o3BX5yOsQ8stRNnAlIF-2FTIuht57CHdYfn0S-2Bdfsdw-3D-3DydEM_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54qTItTBlcVqBiexn1Q3dHb2NUv9yWo3Q53PUeOj-2FW9fCXW9Pvv2HNnM1R2Ab2Z5TlYPygGcuRpWT8Idu-2FA-2F2q2jrJCCMvGmhTk6ot6X0ocjAUaz5NNVB8uv-2BXzQNvJ16Pg-3D-3D)). Jason Wallace: "I'm not a huge fan of the company... elevated utilization of health care resources remained elevated." DOJ criminal upcoding probe and antitrust investigation remain open, with Deep Values framing government rule-changes as "the greatest existential threat." Baird held Underperform at $287. **Debate 2: Can Foundayo (oral GLP-1) catch oral Wegovy?** - **Bull:** Foundayo convenience (no fasting/water restrictions), LillyDirect cash-pay channel, Hims & Hers partnership expanding distribution, $30B peak sales potential per Jefferies. Karnal: Pfizer's undisclosed acquisition "looks like it might be a once-a-month" and Amgen's MariTide targeting "once-a-month, might be once-a-quarter" are farther out ([Invest Like the Best](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgwlKuGttsd3Mz0lWvxs8UIQOezZXf9Yu9ofDQTpgHKEMTbYihaAi18Hm673Ijpsvr4csm826tmGR-2F0tmb3lpN-2BRm5bJNqLnN1i-2BV3UTKh2vQ-3D-3Dqhqi_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54hi5HafEwBR85-2BRjXiIpUZwVECE8Z6seEBSOnA2m5L7gGVRccygpK333Vbg4SsUr-2BHNbCjdpsdrIhA0rwU-2F2vWul6uJSunYvrQkaPJCCZqNH-2Bc0KkE0KagkhLWQHC-2F13VA-3D-3D)). - **Bear:** Week-one scripts (1,390) behind oral Wegovy's launch week (3,071). Novo's peptide-based pill has a first-mover installed base at the same $149 price point. CVS opt-out from BALANCE Model narrows Medicare access. **Debate 3: Medicare GLP-1 coverage, inevitable or stuck?** - **Bull:** Cramer: "They're not obesity drugs. They're health care drugs... It will actually save the system more money than it costs." CVD protection data (20%+ MACE reduction), pre-diabetes prevention (94% reduction), CMS's $245/month BALANCE Model pilot. - **Bear:** UNH's Bobby Hunter flagged "notable challenges and outstanding questions with the currently planned structure." CVS publicly opted out on April 21. The April 20 deadline for insurer commitments may produce insufficient participation for the program to launch in 2027. **Debate 4: Pharma tariffs, front-loaded inventory buffers or margin cliff ahead?** - **Bull:** EU/Japan/Korea/Swiss/UK carve-out at 15%, onshoring tier at 20%, generics/biosimilars/orphans exempt. FiercePharma: global drug production +9% late-2025/early-2026 as firms front-loaded. Companies with MFN "safe harbor" deals shielded. - **Bear:** 100% ad valorem base tariff on imported patented pharma and APIs takes effect July 31, 2026, for designated large manufacturers ([clinicalleader.com](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nuc4Aa4Acjq9FBKhWubUmQA-2BQeRhcOsYynngAsou4onlzVjYsm0ATyhJB4w2lxP8wPJPObD2hW2pQuoZE7oU9-2Bh4D-2BWrysHEtSD-2B-2Bl2mzmLziyDafTwlBIVfl3EAUm7y2A-3D-3D0Mxp_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54o28NSzkj3ufab-2F6bYYsOdRzQfDheha8BiajaPMfljo1CiZfp-2FXy3A6zy9JYlXvvKtF7E7EsYVuEtmI9lOpugPjUX-2FSWWU5ruIcj2XrJhG9AIOUXTC0Te8ppUJtr6uOHmQ-3D-3D)). Notably absent from podcast coverage this week, a blind spot. --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 📈 Emerging Themes - **"Margin over membership" as the managed care playbook.** UNH deliberately shed 80,000 employer/individual members in Q1, the explicit trade for MCR recovery. Deep Values: "You cannot grow your way out of structural unprofitability." - **Dual-lane commercial architecture in pharma.** Lilly's tirzepatide (access/volume) + retatrutide (premium/biologic) is becoming the template: the same company competes against itself on price to maximize total capture under MFN/tariff pressure. - **PCSK9 as the next secular trade behind GLP-1.** Karnal argued PCSK9 inhibitors should "be far bigger... than GLP-1s" long-term, citing "88% reduction in the risk of ever developing cardiovascular disease" in natural PCSK9-deficient populations ([Invest Like the Best](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgwlKuGttsd3Mz0lWvxs8UIQOezZXf9Yu9ofDQTpgHKEMTbYihaAi18Hm673Ijpsvr4csm826tmGR-2F0tmb3lpN-2BRm5bJNqLnN1i-2BV3UTKh2vQ-3D-3DNq_W_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54p42C4TMpRvcUJpgB6N1xNTMLkY0YCEbgxUdlqey9P66fo2hHFAIPH6C2gK2HiA2mm-2BiqPWhXqRvc4mZyCtBgOVps3IboPcLIHrGR-2BKspRx2q-2FuOBqaiATSwrIg-2Bi-2Fbdjw-3D-3D)). Cramer: Amgen's Repatha has label expansion runway. - **In-vivo CAR-T as the next oncology platform.** Lilly/Kelonia at $7B follows the same logic Karnal cited around Capstan: "reduce tumors by 100%... in 70% plus of patients" without ex-vivo manufacturing. - **mRNA cancer vaccine validation.** UCLA pancreatic-cancer data: "Two-thirds of the patients that received the cancer vaccine had a significant immune response... of those, 90% were alive after five years" vs. a historical 13% five-year survival ([Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOirhzPegG85cXoUgPxDb7aS3WZmpbbC5hMqtvECzgiMwbog3msksi6vAfy-2Fot8Cl6jZCrC6LEdv4BuhWprZs-2FYbCWj6L4YUwnm6pCqhOPCKkA-3D-3DExx4_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54tq01GXIWGQN-2BUGpjT3xrOUoHceAXe-2F-2FiRuf6vgqr-2F7KByv7CShbprwIZcKbeKNgDVizJlLtJqOelsa0qlNqSXmjgyhEfJFNBuftq7U8fM0xRQlLJ0kNH5Jc33XN8L87qg-3D-3D)). Read-through: BNTX, MRNA, MRK (Moderna partner). - **AI-enabled operational leverage at payers.** UNH's Optum EMR consolidation from 18 to 3 systems plus 80% call deflection is a template for the sector. --- ## 🤝 Deals & M&A Tracker | Date | Acquirer | Target | Terms | Rationale | | --- | --- | --- | --- | --- | | Apr 20 | Eli Lilly (LLY) | Kelonia Therapeutics | Up to $7B ($3.25B upfront cash + clinical/regulatory/commercial milestones); expected close 2H26 | In-vivo CAR-T platform; lead asset KLN-1010 for multiple myeloma. Guggenheim called out the accompanying $584M IPR&D charge (52c EPS impact). | | Apr 17 | UCB | Neurona Therapeutics | Up to $1.15B ($650M upfront cash) | Regenerative therapies for neurological conditions. | | Apr 6 (ref) | Neurocrine Biosciences | Soleno Therapeutics | $2.9B ($53/share, 34% premium) | Rare-disease franchise expansion. | | (Context) | UnitedHealth | Alegeus | n/a | Management said deal expected to boost 2027 earnings. | Jefferies characterized the setup: "biotech momentum can continue throughout 2026," with Big Pharma appetite spanning $5B+ blockbusters and $1B–$2B tuck-ins ([biobucks.co](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nn4OsbLN94beq6zr0QPXbQTfA7e-2FXbXpTqr3NbwLbsawYGNkjiu0k8vHPFEL2Gsszg-3D-3Dtp1w_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54ol2qxnvkKd1hkZj5mIr0YPnTxoe3lEpuhDAhSD9OhbffOGs-2F8mGJRVoSrP5oAmWe2bq4S-2BLhnkqx-2BjChuVOleMVYv3qmuz1Ws3XFIlefOPR30LpCEjf-2FPhj1n-2BwPdHlHg-3D-3D)). Q1 2026 disclosed biotech deal value totaled ~$44B. --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 🏛️ Regulatory Watch - **CMS, CY2027 MA Rate Announcement (finalized early April):** 2.48% payment increase (~$13B), sharp upward revision from the January 0.09% advance notice ([georgetown.edu](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NtJrilKSAQfr0YsEpWPSSIFk8QCx0Vv3Qdy3I4y70Y6lyfC7ceXzbwSAOgHITggHggH8eJJu28QCmRftnTUBH-2BLZz-2FTuUCTbyB7Y0ZPrSmD4TdGXZnI8xq2e4A6i0R-2FRXmTI8u3iaz35Rrq8M2t7lX43C6QXfDAGDpg4oKihKkRWOy49zzJba-2B7j0ghhXEHOfA-3D-3DZ3zj_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54nD58McXoOasiuCnoy5-2Frtu3E92YkzxtSMO1KOnRlFka8FWatl9rd2GzYxOnSbgy4Moa55atOODCMzNgPOqbFG8KURmZx7Jg-2F3pOoA61mbGiR8ql854RWFRuKEU9DYPxrA-3D-3D)). - **CMS, Final Part C and D Rule (mid-April):** Relaxes marketing restrictions, eliminates 11 Star Rating measures (including call center metrics), reinstates "reward" factor. Estimated $19B cumulative MA plan benefit 2028–2036 ([medicarerights.org](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NnPGhvewswdqCwUz6b-2BupgiWrIGmg8D-2F5tq7gaoVSe0h-2B5e5DUFNzCpvwwDivtonZpFMAC0Rd0NiizuUB0P8saIjmmt8WA9JnSC7c3SIZNusir-2F-2FZtq7hMESLQ9-2B8knc-2BUR0Zz1YgsbhuoHajtc9NExRuoNQocJ2b1sqgA5-2Bnc4aIuvIIL-2Fp7jp952CqLxcj2LuCk6gExWRbPw2aLK94M-2Fw-3DQ4vp_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54pT0Gr2VUPq4d2RpPNvmEz8QeFkWzgf-2FYcBdbozoncueGU7gUNBZD3AhT3NLxAd7XJPnEN5UWyMKuVaYmEwztai5QBL-2FsUZRNwbdQCTy879vmkt5aRD6-2BusKfTOhBIqrxQ-3D-3D)). - **CMS, BALANCE Model for GLP-1s:** Insurers had until April 20 to commit to 2027 participation. UNH raised "notable challenges"; CVS opted out; program requires majority insurer participation to proceed. - **FDA, Foundayo (orforglipron) Phase 3 ACHIEVE-4:** Primary endpoint met; T2D filing under Priority Review Voucher by end of Q2. - **FDA, Sparsentan approved April 14** for Focal Segmental Glomerulosclerosis. - **FDA, peptide reclassification:** 12 peptides removed from restricted status. Jason Wallace: "Banning them actually makes it less safe" because gray-market products "from China... have very inconsistent results... many of them contain significant amounts of heavy metals" ([Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOirhzPegG85cXoUgPxDb7aS3WZmpbbC5hMqtvECzgiMwbog3msksi6vAfy-2Fot8Cl6jZCrC6LEdv4BuhWprZs-2FYbCWj6L4YUwnm6pCqhOPCKkA-3D-3DXbuB_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54ropmz-2FXeYBUjFy7ZrPRL-2Fg82j5BiPf7WKgaoXagRbKe1VNNeMu26Ps2K1fv5zI-2BWiSV9Z5dbjLmLgc-2Fj8-2Be3W5IFyS4NeK-2BlWYN2P-2B0Yso4GIHpqvyzlfSi4YfnnnQ2DQ-3D-3D)). - **Section 232 pharma tariffs (law April 2):** 100% ad valorem base tariff on imported patented pharma/APIs. Effective July 31, 2026 for designated large manufacturers; September 29, 2026 for others. EU/Japan/Korea/Swiss/UK at 15%; onshoring pledge tier at 20%; generics/biosimilars/orphan drugs exempt ([clinicalleader.com](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nuc4Aa4Acjq9FBKhWubUmQA-2BQeRhcOsYynngAsou4onlzVjYsm0ATyhJB4w2lxP8wPJPObD2hW2pQuoZE7oU9-2Bh4D-2BWrysHEtSD-2B-2Bl2mzmLziyDafTwlBIVfl3EAUm7y2A-3D-3DJT8I_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54vW6QWWmfoUE6ohxqKXE-2BQ-2F6z9oApMzkGTuUmmw-2FJ-2BvuQ8yQ4UTO5Cmys1C-2BteroO9UvnzZxXdP52r5nL5BdiHnj-2Bl8b2N3equ5oNFk6-2FOH-2BVEtfGNQyPmVPMuDGIQRFsQ-3D-3D)). - **Leadership:** Trump nominated Dr. Erica Schwartz (former Deputy Surgeon General) as CDC Director; Wallace called it "a really uncontroversial pick and a great pick to bring stability." - **Retatrutide biologic classification:** Lilly appealed to the Seventh Circuit in March 2026 after a December 2025 ruling vacated the FDA's denial. Decision pending; a win grants 12 years of exclusivity and restricts compounding. - **DOJ:** UnitedHealth criminal upcoding probe and antitrust investigation into UnitedHealthcare+Optum vertical integration remain open. --- ## 🗓️ Week Ahead **Earnings / data to watch:** - Managed care read-through continues. Elevance (ELV) already reported April 22 with a $935M CMS risk-adjustment accrual; Humana (HUM) and CVS on deck. - Large-cap pharma Q1 prints from MRK, PFE, ABBV, BMY in the coming two weeks will test whether the GLP-1 / oncology narratives extend. - LLY Q1 earnings: GLP-1 franchise numbers, initial Foundayo commentary, Kelonia accounting treatment. **Catalysts flagged in this week's podcasts:** 1. Lilly H2 2026 Alzheimer's early-intervention data. Karnal expects "dramatic effects on protecting us from developing Alzheimer's." 2. Seventh Circuit ruling on retatrutide biologic classification. 3. Novo Nordisk CagriSema FDA decision expected late 2026. 4. Medicare BALANCE Model go/no-go determination after April 20 deadline. 5. Foundayo weekly script tracking, IQVIA data through April/May as sales ramp. 6. Amazon GLP-1 distribution expansion to 4,500 cities by year-end. 7. DOJ update / next procedural step in UNH investigations. 8. July 31 pharma tariff effective date for designated large manufacturers. **Known coverage gaps this week:** J&J (JNJ), AbbVie (ABBV), Merck (MRK) Q1 reactions and Intuitive Surgical (ISRG) / medtech commentary were largely absent from podcast coverage despite being in-quarter; worth watching next week. --- ## Sources - [Squawk on the Street, Jim Cramer on UNH](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOglavA94VgO9SzqIWCK7LtYgRbge6YFefmuB2tH6CL5jLXNFg2BzCKw1ewhxqDoxRmfRHy62HhWhLkrWfegXomxknD7-2BMb-2FFlOvfUKuinw9JQ-3D-3DMwSI_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54qu1RCdFPiNFPaMy44-2BWf4nV4vt9JsFZF46XWTlkn8tkNeJPxGdj-2BGeH1iuU5W2aJGQupq-2BHKSstxyjETlsFTJ9rRExB9fKABC16rtpWTyHPLWWzGr53jkXq8odv5AHJ1g-3D-3D) - [Brew Markets, UNH / Amazon GLP-1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjtav12niUMNSn49mvn6b8P4PjgAqlRPPCuZCt5jvRWgr56kGnu0FFC-2Fwo9868KxN-2BFPNLhFcQqnWgydyuxqs6LLIzUYKPXK1k3Cujh-2B36FWw-3D-3DHYSO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54usOlATcCd-2FFjTnK9YS566QgwXuLJeMvWl1cYMyp95v2t-2FFRNOUsGXpSFSO5XulPAP8V97gY3eM38UIyIsny04LWtacR7YpftHUZ0gSLvOwKuEvVEuYo-2BEITfLVrkzqXVw-3D-3D) - [Invest Like the Best, Alex Karnal on GLP-1 / PCSK9](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgwlKuGttsd3Mz0lWvxs8UIQOezZXf9Yu9ofDQTpgHKEMTbYihaAi18Hm673Ijpsvr4csm826tmGR-2F0tmb3lpN-2BRm5bJNqLnN1i-2BV3UTKh2vQ-3D-3DFAAy_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54ubCXp3KLaJ-2B6F6jgZAq7nHMHmi8vYG3Z7LYBHI7X3qWSkgKUQLnD2R1IVyh-2B-2B7BXizhw-2Bayyla-2B7cy48vS0USkxtaANH-2Fgw3nGHYr1MiN3e94tVb8npxGkhJdfJGaFnfQ-3D-3D) - [On The Pen, Dave Knapp on Lilly dual-lane strategy](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgKJjbpH-2FkkM4a-2B-2F0Rwt6wyImQtFtfN7gqsf5-2FKj8wjc9QgngaY7zqp8WzkdFBTu0VvpdITttWJx9QMlnWKMqg1MmIAZeb-2F39aVysL28dT9Sw-3D-3DQjPh_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54pcX-2BacvLWswjNjfkafSUnO62bKYh1dy6Lw8Y4RxSe8llZTgwYMJo5pTvZoKQXCBnmc2VIUHp8FIX2fd9E2R4N0OiKFSyNTsg0mAgx4BQN-2FUXHWlN48IvhBE4S1B-2BEsfAw-3D-3D) - [Telltales, Jason Wallace on UNH / Kelonia / FDA peptides](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOirhzPegG85cXoUgPxDb7aS3WZmpbbC5hMqtvECzgiMwbog3msksi6vAfy-2Fot8Cl6jZCrC6LEdv4BuhWprZs-2FYbCWj6L4YUwnm6pCqhOPCKkA-3D-3DvcrY_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54jALJ13DkyxkkSjs7yXzyAKP7VaMuxnGtrZJ8BetV2W9Txy2e77mQdQFaH5dvd-2B7sCkspNf7ELrbsm-2B0Vnln6wYQLKfm39AkdzTmkVvGL6-2FiiJxwgrEqZgVeyfzbTDL5OQ-3D-3D) - [Telltales Weekend Update, UNH pre-earnings setup](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjKXhPgQj-2FqoQzjop2G3kAOXt5F0OoJ0rujDHfVQMgizsOjpYOzPCnCoXK9kJPpr1-2FCSFag4tV-2FuRtVpVhAaBNc4ScV8dmCuGxXdGy5zvtWYA-3D-3DL-1K_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54tbiBJIOt7fBd-2BbmyZk-2FZoAvQWatsC-2FYdDQlHynbtzgsyZAVCeiLARwXCFYLJMaIumhuodGBfLGLXA4tBnmE2TbtSyIK-2FR3rbg7-2BVpEM9-2BII-2Fcsj3U8nwr9PnCJP5z-2B4UQ-3D-3D) - [Deep Values, UNH valuation](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgV3h26SZXwcsYB9EiNOQUb-2BjJvhZK7vb-2Bat4LVxXSdN-2FdfJw9DtZObV5PvtOdTMEFj5o3BX5yOsQ8stRNnAlIF-2FTIuht57CHdYfn0S-2Bdfsdw-3D-3DScwD_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54hH94jZulcLXoCj24I9FO7d0u6xqCia1HaZ2U6jX6fNK-2BwSFjFVonJnBIPoAhzMDvEyBji3Nyp1rbgP8roPUrsMaUjtEy-2FDwWeuCOs4bcGvTg9t2ZARnGNbtFuOCUFLcXA-3D-3D) - [Motley Fool Money, Amazon GLP-1 disruption](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOirhzPegG85cXoUgPxDb7aSxN5WWw9N8L8YBrq8fd4yXoV0u7jHwRQ3HZhVJ5rsH88ed2mTowXH-2BwGEo7hOI1b7YgaEnhW14On-2FUuU7sFOjWg-3D-3Dgh1H_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54kRUiyiO51YWhRcfGcMbs6p8IR4u8y12k2sRQJZE3jrfjY41kBBLyOfPQedK6ITruf7DYciForcbAdZUNAVsO-2FQX8kOsbLcxnvrnJNqlM8e5SDAdEReweEtBPsBaIZDtRg-3D-3D) - [Jefferies biotech outlook, biobucks.co](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nn4OsbLN94beq6zr0QPXbQTfA7e-2FXbXpTqr3NbwLbsawYGNkjiu0k8vHPFEL2Gsszg-3D-3Dtp1w_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54ol2qxnvkKd1hkZj5mIr0YPnTxoe3lEpuhDAhSD9OhbffOGs-2F8mGJRVoSrP5oAmWe2bq4S-2BLhnkqx-2BjChuVOleMVYv3qmuz1Ws3XFIlefOPR30LpCEjf-2FPhj1n-2BwPdHlHg-3D-3D) - [Foundayo launch tracking, biopharmadive.com](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nj6bujixd4sULtqXs3KXTyNcZNKJQXxArtCH0bXYz3u61aIDm5kdTfqN5u8uOHJB0d7LxCToansg2HB7yuZ-2Bd6JmtqzL0EVjwSwQ0KmaclR5rDrNOkxVJdSlNuf2xqPrKw-3D-3Dd0rg_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54qA2qDmzem2zkggrlWFxGseKrcJsK7a-2B2x1DR3O5J-2F95Gb6W-2FenBEconYq2oRIo-2Boc87CMBJ1vvrLXCW1DVQUPD4Bg8Pq3JKkxNWEf2xJGqyswFYuA9HTOPR1opsDhFAbw-3D-3D) - [Foundayo launch tracking, fiercepharma.com](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NorSeiv-2BtvhOFU8-2F32T8ecM-2BirjJpN-2BL0rhfqSScEfF83kTUj4WrjnarbiwFdymhBX2YW-2Fn4vFiVvuFz5-2FlXZMLGJqorT066LaIcMmPyz7n8nBlNOpv-2BvdwYT8BO0AZzjSv9T8hmRbPgN-2F72-2BWj1keo-3DDl18_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54mouR8QeevaYJ-2BZeERpsX1mAGma3fn85HFG3-2F6tNHhvVir0aUcMUur2p5dQ6BoVNo7l6zmbnG1zDhfm4EA7SXsxSVXo-2BZ2fFU58KuYeAmKSoHzo0Be-2B2-2BRzVQVjW7WFw2w-3D-3D) - [CY2027 MA Rate Announcement, georgetown.edu](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NtJrilKSAQfr0YsEpWPSSIFk8QCx0Vv3Qdy3I4y70Y6lyfC7ceXzbwSAOgHITggHggH8eJJu28QCmRftnTUBH-2BLZz-2FTuUCTbyB7Y0ZPrSmD4TdGXZnI8xq2e4A6i0R-2FRXmTI8u3iaz35Rrq8M2t7lX43C6QXfDAGDpg4oKihKkRWOy49zzJba-2B7j0ghhXEHOfA-3D-3DZ3zj_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54nD58McXoOasiuCnoy5-2Frtu3E92YkzxtSMO1KOnRlFka8FWatl9rd2GzYxOnSbgy4Moa55atOODCMzNgPOqbFG8KURmZx7Jg-2F3pOoA61mbGiR8ql854RWFRuKEU9DYPxrA-3D-3D) - [Final Part C and D Rule, medicarerights.org](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NnPGhvewswdqCwUz6b-2BupgiWrIGmg8D-2F5tq7gaoVSe0h-2B5e5DUFNzCpvwwDivtonZpFMAC0Rd0NiizuUB0P8saIjmmt8WA9JnSC7c3SIZNusir-2F-2FZtq7hMESLQ9-2B8knc-2BUR0Zz1YgsbhuoHajtc9NExRuoNQocJ2b1sqgA5-2Bnc4aIuvIIL-2Fp7jp952CqLxcj2LuCk6gExWRbPw2aLK94M-2Fw-3DQ4vp_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54pT0Gr2VUPq4d2RpPNvmEz8QeFkWzgf-2FYcBdbozoncueGU7gUNBZD3AhT3NLxAd7XJPnEN5UWyMKuVaYmEwztai5QBL-2FsUZRNwbdQCTy879vmkt5aRD6-2BusKfTOhBIqrxQ-3D-3D) - [Section 232 pharma tariffs, clinicalleader.com](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nuc4Aa4Acjq9FBKhWubUmQA-2BQeRhcOsYynngAsou4onlzVjYsm0ATyhJB4w2lxP8wPJPObD2hW2pQuoZE7oU9-2Bh4D-2BWrysHEtSD-2B-2Bl2mzmLziyDafTwlBIVfl3EAUm7y2A-3D-3DJT8I_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXyxthwv6LoagsI6B0GO-2BGRUDtlrqNeY4MIvkjKF0b54vW6QWWmfoUE6ohxqKXE-2BQ-2F6z9oApMzkGTuUmmw-2FJ-2BvuQ8yQ4UTO5Cmys1C-2BteroO9UvnzZxXdP52r5nL5BdiHnj-2Bl8b2N3equ5oNFk6-2FOH-2BVEtfGNQyPmVPMuDGIQRFsQ-3D-3D) --- --- ```request-access variant: banner heading: Run your own corpus. description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage. buttonText: Request access ```